Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease

被引：18

作者：

Basso, IN

Keeling, D ^{[1
]}

机构：

[1] Churchill Hosp, Oxford Haemophilia Ctr, Oxford OX3 7LJ, England

[2] Churchill Hosp, Thrombosis Unit, Oxford OX3 7LJ, England

来源：

BLOOD COAGULATION & FIBRINOLYSIS | 2004年 / 15卷 / 06期

关键词：

myocardial infarction; recombinant activated factor VII;

D O I：

10.1097/00001721-200408000-00010

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We describe a 50-year-old man with von Willebrand disease type 2A who suffers from angiodysplasia and has required many transfusions for gastro-intestinal haemorrhage. Various investigative modalities have not demonstrated a single source for this. Following a case report of successful use of recombinant activated factor VII (NovoSeven(R); Novo Nordisk, Copenhagen, Denmark), the patient was treated with it but suffered a large myocardial infarct. As the patient has risk factors for atherosclerotic disease, we presume the recombinant activated factor VII promoted coagulation at a pre-existing atherosclerotic lesion.

引用

页码：503 / 504

页数：2

共 9 条

[1] Tissue-factor antigen and activity in human coronary atherosclerotic plaques [J].

Ardissino, D ;

Merlini, PA ;

Ariens, R ;

Coppola, R ;

Bramucci, E ;

Mannucci, PM .

LANCET, 1997, 349 (9054) :769-771

[2] Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors [J].

Hough, RE ;

Hampton, KK ;

Preston, FE ;

Channer, KS ;

West, J ;

Makris, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2000, 111 (03) :974-979

[3] Recurrent severe bleeding from gastrointestinal angiodysplasia in a patient with von Willebrand's disease, controlled with recombinant factor VIIa [J].

Meijer, K ;

Peters, FTM ;

van der Meer, J .

BLOOD COAGULATION & FIBRINOLYSIS, 2001, 12 (03) :211-213

[4] Use of recombinant factor VIIa (NovoSeven®) in patients with Glanzmann thrombasthenia [J].

Poon, MC ;

d'Oiron, R ;

Hann, I ;

Négrier, C ;

de Lumley, L ;

Thomas, A ;

Karafoulidou, A ;

Demers, C ;

Street, A ;

Huth-Kühne, A ;

Petrini, P ;

Fressinaud, E ;

Morfini, M ;

Tengborn, L ;

Marquès-Verdier, A ;

Musso, R ;

Devecioglu, O ;

Houston, DS ;

Lethagen, S ;

Van Geet, C ;

von Depka, M ;

Berger, C ;

Beurrier, P ;

Britton, HA ;

Gerrits, W ;

Guthner, C ;

Kuhle, S ;

Lorenzo, JJ ;

Makris, PE ;

Nohe, N ;

Paugy, P ;

Pautard, B ;

Torchet, MF ;

Trillot, N ;

Vicariot, M ;

Wilde, J ;

Winter, M ;

Chambost, H ;

Ingerslev, J ;

Peters, M ;

Strauss, G .

SEMINARS IN HEMATOLOGY, 2001, 38 (04) :21-25

[5] Safety profile of recombinant factor VIIa [J].

Roberts, HR ;

Monroe, DM ;

Hoffman, M .

SEMINARS IN HEMATOLOGY, 2004, 41 (01) :101-108

[6] Clinical liver transplantation [J].

Roberts, J .

AMERICAN JOURNAL OF TRANSPLANTATION, 2001, 1 (01) :18-20

[7] MORTALITY AND CAUSES OF DEATH IN DUTCH HEMOPHILIACS, 1973-86 [J].

ROSENDAAL, FR ;

VAREKAMP, I ;

SMIT, C ;

BROCKERVRIENDS, AHJT ;

VANDIJCK, H ;

VANDENBROUCKE, JP ;

HERMANS, J ;

SUURMEIJER, TPBM ;

BRIET, E .

BRITISH JOURNAL OF HAEMATOLOGY, 1989, 71 (01) :71-76

[8]

SULLIVAN DW, 1984, PEDIATRICS, V74, P279

[9]

Tengborn L, 1996, THROMB HAEMOSTASIS, V75, P981

← 1 →